Siegfried (SIX: SFZN), a leading global Contract Development and Manufacturing Organization (CDMO), announced the appointment of Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. This appointment follows the company's decision to combine the COO roles for Drug Substances and Drug Products into one position, aligning with Siegfried's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Eduardo Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Previously, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks.
With his strong track record in integrated operations, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network. The company operates 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China. In 2025, Siegfried achieved sales of CHF 1,327.8 million and employed more than 3,800 people.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, stated: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Eduardo Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He has extensive international leadership experience, having lived and worked across Europe and Latin America.
This strategic appointment underscores Siegfried's commitment to delivering high-quality, reliable services to its pharmaceutical clients. By consolidating operational leadership, the company aims to better integrate its drug substance and drug product capabilities, offering seamless end-to-end solutions that can accelerate time-to-market for new therapies. For the pharmaceutical industry, this move signals Siegfried's focus on operational excellence, which could translate into more efficient manufacturing processes and potentially lower costs for drug developers. Investors may view this as a positive step toward improving margins and competitiveness in the CDMO market.
